You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Long-Term Management of Ovarian Cancer: An In-Depth Analysis of the Latest Clinical Data

  • Authors: Nicoletta Colombo, MD; Susana Banerjee, MBBS, MA, FRCP, PhD; Kathleen N. Moore, MD
  • CME Released: 11/23/2022
  • Valid for credit through: 11/23/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, obstetricians, gynecologists, and surgeons.

The goal of this activity is for learners to be better able to contextualize and understand the key data sets and long-term outcomes in ovarian cancer based on the presentations from the European Society for Medical Oncology (ESMO) 2022.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Long-term data in patients who may benefit from receiving poly(ADP-ribose) polymerase (PARP) inhibitor therapy for ovarian cancer
    • Recent clinical trial results evaluating long-term outcomes in patient with ovarian cancer
  • Demonstrate greater confidence in their ability to
    • Optimally select patients who are likely to have improved long-term outcomes from therapy with PARP inhibitors


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Nicoletta Colombo, MD​, PhD

    Associate Professor of Obstetrics and Gynecology
    University of Milan-Bicocca
    Director ​
    Program of Gynecologic Oncology ​
    European Institute of Oncology ​
    Milan, Italy

    Disclosures

    Nicoletta Colombo, MD, has no relevant financial relationships.

  • Susana Banerjee, MBBS, MA, FRCP, PhD

    Consultant Medical Oncologist
    Research Lead Gynecological Cancers
    The Royal Marsden NHS Foundation Trust
    Reader in Women's Cancers
    The Institute of Cancer Research
    London, United Kingdom

    Disclosures

    Susana Banerjee, MBBS, MA, FRCP, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; AstraZeneca; Epsilogen; Genmab; GlaxoSmithKline; ImmunoGen; Merck Sharp & Dohme; Merck Sereno; Mersana; OncXerna; Pfizer; Roche; Shattuck Labs
    Speaker or member of speakers bureau for: Amgen; AstraZeneca; Clovis; GlaxoSmithKline; Immunogen; Merck Sharp & Dohme; Mersana Therapeutics; Pfizer; Takeda
    Research funding from: AstraZeneca; GlaxoSmithKline
    Other: European Society Medical Oncology Director of Membership (no financial renumeration)

  • Kathleen N. Moore, MD ​

    Professor, Section of Gynecologic Oncology ​
    Jim and Christy Everest Endowed Chair in Cancer Research ​
    Director, Oklahoma TSET Phase I Program ​
    OU Stephenson Cancer Center ​
    Oklahoma University College of Medicine ​
    Oklahoma, United States

    Disclosures

    Kathleen N. Moore, MD, has the following relevant financial relationships:
    Consultant or advisor for: Alkemeres; Aravive; AstraZeneca; Blueprint Medicines; Clovis Oncology; Eisai; EMD Serono; Genentech/Roche; GlaxoSmithKline/Tesaro; Hengrui; ImmunoGen; I-Mab; Lilly; Merck & Co.; Mereo; Mersana Therapeutics; Myriad Genetics; Novartis; OncXerna Therapeutics; OncoNova Therapeutics; Tarveda; VBL Therapeutics; Verastem Oncology
    Research funding from: GlaxoSmithKline/Tesaro; Lilly; Merck & Co.; PTC Therapeutics; Verastem Oncology
    Monetary compensation for an executive role from: GOG Partners

Editors

  • Keisha Peters, MSc

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Keisha Peters, MSc, has no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Long-Term Management of Ovarian Cancer: An In-Depth Analysis of the Latest Clinical Data

Authors: Nicoletta Colombo, MD; Susana Banerjee, MBBS, MA, FRCP, PhD; Kathleen N. Moore, MDFaculty and Disclosures

CME Released: 11/23/2022

Valid for credit through: 11/23/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to contextualize and understand the key data sets and long-term outcomes in ovarian cancer based on the presentations from the European Society for Medical Oncology (ESMO) 2022.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print